MARKET

VOR

VOR

Vor Biopharma Inc.
NASDAQ
3.980
+0.080
+2.05%
After Hours: 3.980 0 0.00% 16:48 09/30 EDT
OPEN
4.000
PREV CLOSE
3.900
HIGH
4.090
LOW
3.730
VOLUME
57.24K
TURNOVER
0
52 WEEK HIGH
18.52
52 WEEK LOW
3.730
MARKET CAP
151.46M
P/E (TTM)
-1.8283
1D
5D
1M
3M
1Y
5Y
BRIEF-Vor Bio Initiates In-House Clinical Manufacturing At Cambridge, Ma Headquarters
BRIEF-Vor Bio Initiates In-House Clinical Manufacturing At Cambridge, Ma Headquarters
Reuters · 2d ago
Why Virios Therapeutics Is Trading Lower By 75%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 51% to $0.4957. Crown ElectroKinetics, last month, posted a Q4 net loss of $4.5 million.
Benzinga · 09/20 16:41
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: Morgan Stanley 20th Annual Global Hea...
GlobeNewswire · 09/06 20:15
How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 295%
The consensus price target hints at a 295% upside potential for Vor Biopharma Inc. (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witnes...
Zacks · 08/16 13:55
--HC Wainwright Adjusts Vor Biopharma's Price Target to $20 From $26, Keeps Buy Rating
--HC Wainwright Adjusts Vor Biopharma's Price Target to $20 From $26, Keeps Buy Rating
MT Newswires · 08/15 08:56
--Stifel Adjusts Vor Biopharma's Price Target to $21 from $24, Keeps Buy Rating
--Stifel Adjusts Vor Biopharma's Price Target to $21 from $24, Keeps Buy Rating
MT Newswires · 08/12 12:40
BRIEF-Vor Bio Reports Q2 Net Loss $21.7 Mln
BRIEF-Vor Bio Reports Q2 Net Loss $21.7 Mln
Reuters · 08/11 20:55
--Wedbush Starts Vor Biopharma at Outperform With $18 Price Target
--Wedbush Starts Vor Biopharma at Outperform With $18 Price Target
MT Newswires · 07/26 04:41
More
About VOR
Vor Biopharma Inc. is a clinical-stage cell therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. VOR33 is the lead product candidate consisting of genome-edited hematopoietic stem and progenitor cells that have been engineered to lack the CD33 protein. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of VOR33 in participants with AML. It offers VCAR33 programs that are chimeric antigen receptor T (CAR-T) cell therapy candidates designed to target CD33.

Webull offers kinds of Vor Biopharma Inc stock information, including NASDAQ:VOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VOR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VOR stock methods without spending real money on the virtual paper trading platform.